Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-SOD1 in SOD1-ALS
NCT05949294Phase 1Withdrawn
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
01
Overview
Phase 1, open-label, single-arm trial of ARO-SOD1 in amyotrophic lateral sclerosis (ALS), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events at Day 168. Planned start Jan 2024; status: withdrawn.
02
Drugs
ARO-SOD1
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05949294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949294.